Rational Advisors’s Gyre Therapeutics GYRE Stock Holding History

Rational Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,240	Closed	-$197K	–	565
2019 Q1	$197K	Buy	+3,240	New	+$208K	0.05%	201

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Rational Advisors's GYRE Position: Q2 2019 in Review

Rational Advisors sold out of Gyre Therapeutics (GYRE) in Q2 2019, closing a stake of 3,240 shares — an estimated $197K sold.

Rational Advisors first reported a position in GYRE in Q1 2019 and held it in 1 quarter. The position peaked at $197K in Q1 2019. 49 funds tracked by Wall St. Rank hold GYRE as of Q2 2019.

Rational Advisors reported no remaining Gyre Therapeutics position as of Q2 2019 after selling out during the quarter.
Rational Advisors sold 3,240 Gyre Therapeutics shares in Q2 2019, an estimated $197K.
Rational Advisors first reported a position in Gyre Therapeutics in Q1 2019 and held it in 1 quarter.
Rational Advisors's Gyre Therapeutics position peaked at $197K in Q1 2019.
49 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2019.

Based on Rational Advisors's 13F filing for Q2 2019, filed 8 Aug 2019.